Back to Journals » Vascular Health and Risk Management » Volume 4 » Issue 4

Fixed combinations in the management of hypertension: perspectives on lercanidipine – enalapril

Authors Barrios V, Escobar C, Echarri R

Published 8 August 2008 Volume 2008:4(4) Pages 847—853

DOI https://doi.org/10.2147/VHRM.S3421

Review by Single-blind

Peer reviewer comments 4


Vivencio Barrios1, Carlos Escobar2, Rocio Echarri3

1Department of Cardiology, Hospital Ramón y Cajal, Madrid; 2Department of Cardiology, Hospital Infanta Sofia, Madrid, 3Department of Nephrology, Hospital Infanta Sofia, Madrid

Abstract: Although achieving blood pressure (BP) control is critical to improve cardiovascular prognosis in hypertensive patients, many of them fail to achieve BP goals. The majority of hypertensive patients need more than one antihypertensive agent to attain BP targets. Combination therapy is required when monotherapy fails to attain BP objectives and as a first-line treatment in certain situations, such as markedly elevated BP values, when lower targets are required in high or very high cardiovascular risk patients. The advantages of combination therapy are well documented, with an increased antihypertensive efficacy as a result of the simultaneous inhibition of different mechanisms of action and with a lesser incidence of adverse events, because of the possible compensatory responses and the lower doses used. Calcium channel blockers are effective drugs in the treatment of hypertension. The efficacy of lercanidipine has been evaluated in several noncomparative and in comparative studies showing a great efficacy with a good tolerability. On the other hand, the inhibition of the renin-angiotensin system appears to be very beneficial in the treatment of patients with hypertension. Enalapril is an effective and well tolerated angiotensin converting enzyme inhibitor. Although there are several fixed-combination drugs, the combination lercanidipine plus enalapril appears to be one of the most promising therapies in the treatment of hypertension. The aim of this manuscript is to update the published data about the efficacy and safety of this fixed combination.

Keywords: angiotensin converting enzyme inhibitors, calcium channel blockers, combination therapy, hypertension, lercanidipine, enalapril

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]